




RealRate

PHARMACEUTICAL 2012

Oncotelic Therapeutics Inc
Rank 95 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 263%, being 29% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	10,647
Cost of Goods Sold	0
Intangible Assets	289
Liabilities, Current	2,253
Liabilities, Non-Current	0
Other Assets	86
Other Compr. Net Income	0
Other Expenses	1,226
Other Liabilities	6.0
Other Net Income	2,239
Other Revenues	0
Property and Equipment	34
Research and Development	5,291
Selling, General and Administrative Expense	5,375

Output Variable	Value in 1000 USD
Assets	11,056
Liabilities	2,259
Expenses	11,892
Revenues	0
Stockholders Equity	8,797
Net Income	-9,653
Comprehensive Net Income	-9,653
BaseVar	13,723
ECR before LimitedLiability	143%
Economic Capital Ratio	263%